Skip to main content

Treatment Resistance in Psychotic Disorders

Cover image for Research Topic "Treatment Resistance in Psychotic Disorders"
80kviews
Editorial21 March 2023
Editorial: Treatment resistance in psychotic disorders

Pharmacological therapy with antipsychotics takes the centre stage in their management, while psychotherapies also supplement them to constitute what is described as the holistic care in the management plan of psychotic disorders (3). Antipsychotics have evolved ever since chlorpromazine and clozapine were discovered in the 1950s. Over the years, various types and chemical classes of antipsychotics have been discovered and they have been used for the treatment of schizophrenia, in particular, and psychosis in general with varying response rates.While the dopamine hypothesis of psychosis was the leading theory to guide the development of antipsychotics, newer lines of evidence have also incorporated the role of serotonin, GABA, glutamate, and even nicotinic cholinergic neurotransmission in the pathogenesis of psychotic disorders, thus paving the way to newer antipsychotics with fewer adverse reactions, albeit with varying degrees of success (4). To this day, managing psychosis is a challenge to psychiatrists worldwide, and the psychopharmacological armamentarium to treat psychotic disorders is of little success. Around 30% of the sufferers of psychosis continue to have significant morbidity and disability after standard antipsychotic treatment, i.e. they develop treatment resistance (5). Treatment resistance in psychosis is defined as inadequate therapeutic response to at least two adequate trials of antipsychotics. This leads to significant impairment in the individual sufferer and inflates healthcare utilization and costs of treatment (6). Till date, clozapine has been the only antipsychotic approved for treatment resistant schizophrenia (a prototype of psychosis), but it is associated with some common and serious adverse effects (7).When clozapine fails, the management becomes more difficult, and this is associated with a poorer outcome.Treatment resistance in psychotic disorders thus poses significant challenges both to sufferers and to mental health professionals. Since the gamut of psychotic disorders is large as far as individual diagnostic groups in nosology are concerned, no particular management plan of treatment resistance for one group of psychosis is a good fit for others. There are putative differences in our neurobiological understandings of these different psychotic disorders and also their treatments. The current research topic attempted to address treatment resistance in psychosis (TRP) from a holistic perspective. Researchers were invited to submit papers addressing different aspects of TRP, and the current topic collection mirrors their submissions.Total six submissions were received of which two are original research, one brief research report, two mini reviews and one perspective article.Of the two original research articles, the first by Samuel et al. was undertaken in a psychiatric institution in Ethiopia, wherein the authors aimed to assess the association between social support and psychotic relapse in patients with schizophrenia. They recruited 396 patients with schizophrenia and involving a case-control model, they found social support to be a significant contributor of schizophrenia relapse with poorer support being associated with higher odds of relapse (odds ratio: 3.102). The authors emphasized that both family members and mental hospitals should increase support to patients with schizophrenia that has a bearing on the prognosis. The second by Lappin et al. was conducted in Australia, wherein the authors assessed how much of the recommended treatment options (clozapine and/ or ECT) for treatment resistant psychosis (TRP) is actually practiced in a real-world situation. The authors reported that though around 89% of those who are fulfilling criteria for TRP had received clozapine at some point, only 39% of them are currently being prescribed the drug. The utilization of ECT (25%) was however poorer than clozapine. They also noted that a full trial of clozapine was seldom attempted (median trial duration: 4 months) and clozapine plasma levels were also rarely measured. They concluded with a note that there need to be strategies to optimize the utilization of clozapine and ECT for those with TRP for adequate therapeutic effectiveness and overall well-being. Taken together, these articles have provided some light into the enigmatic concept of TRP and its management, while paving the pathway for future research on this area.

3,719 views

3 citations

MINI REVIEW
24 February 2023
Treatment resistant psychosis in children and adolescents and clozapine: Nuances
Jigyansa Ipsita Pattnaik, 3 more and Jayaprakash Russell Ravan

12,048 views

15 citations

ORIGINAL RESEARCH
6 September 2022
Underuse of recommended treatments among people living with treatment-resistant psychosis
Julia M. Lappin, 2 more and Ishan C. Walpola

4,088 views

10 citations